Should clomiphene citrate (CC) [clomifene] or low-dose gonadotrophin therapy [follitropin-beta; follitropin/recombinant follicle-stimulating hormone; Puregon] be the first-line treatment for anovulatory infertility associated with polycystic ovary syndrome? A multicentre, randomized, prospective study and cost effective analysis

Trial Profile

Should clomiphene citrate (CC) [clomifene] or low-dose gonadotrophin therapy [follitropin-beta; follitropin/recombinant follicle-stimulating hormone; Puregon] be the first-line treatment for anovulatory infertility associated with polycystic ovary syndrome? A multicentre, randomized, prospective study and cost effective analysis

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Aug 2009

At a glance

  • Drugs Follitropin beta (Primary) ; Clomifene
  • Indications Infertility
  • Focus Therapeutic Use
  • Acronyms COFFI
  • Most Recent Events

    • 11 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top